GO:0016266 protein O-linked glycosylation via N-acetylgalactosamine: O-GalNAc Glycosylation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016266 describes the biosynthetic process that begins with covalent attachment of N-acetylgalactosamine (GalNAc) via an alpha-glycosidic bond to serine or threonine residues of proteins, forming the Tn antigen and initiating mucin-type O-glycan elongation.
• This process is initiated by a large family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases (GALNTs), which show tissue-specific expression and substrate selectivity.
• O-GalNAc glycosylation is functionally important in cancer, where GALNT7 and GALNT4 promote hepatocellular carcinoma and non-small cell lung cancer progression through O-glycosylation of MUC13 and MUC5AC, respectively.
• In the nervous system, GalNAc-T13 maintains neurite architecture and memory retention via O-GalNAc glycosylation of seizure protein 6.
• O-GalNAc glycans on host mucus can act as inhibitory signals for Salmonella Typhimurium SPI-1-mediated invasion.
• The N-acetylgalactosamine salvage pathway can be exploited to metabolically label O-linked glycoproteins, providing a powerful tool for detecting O-GalNAc-modified proteins.
Description
Protein O-linked glycosylation via N-acetylgalactosamine (GO:0016266) is a glycoprotein biosynthetic process that begins with the covalent linkage of an N-acetylgalactosamine (GalNAc) via an alpha-glycosidic bond to the oxygen atom of a serine or threonine side chain in a protein. This initial step, often referred to as mucin-type O-glycosylation or O-GalNAcylation, can be further elongated with the sequential addition of sugar units, resulting in the formation of a mature protein O-linked glycan. The process is initiated by a family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases (GALNTs), which transfer GalNAc from UDP-GalNAc to acceptor hydroxyl groups on target proteins. Because O-GalNAc glycans decorate a large fraction of secreted and membrane proteins, this modification influences protein stability, folding, trafficking, and interactions with lectins and signaling receptors.
protein O-linked glycosylation via N-acetylgalactosamine At A Glance
| GO ID | GO:0016266 |
|---|---|
| GO term | protein O-linked glycosylation via N-acetylgalactosamine |
| Ontology | biological_process |
| Synonym | core O-glycan biosynthetic process; mucin-type O-glycan synthesis; O-glycan processing; protein O-linked GalNAcylation; protein O-linked glycosylation via N-acetylgalactosamine |
| Major function | Initiates and elaborates mucin-type O-glycans on serine/threonine residues of proteins, affecting protein stability, trafficking, and cell signaling. |
| Initial enzyme | UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases (GALNTs) transfer GalNAc to Ser/Thr. |
| Key substrate | UDP-N-acetylgalactosamine (UDP-GalNAc) as the sugar donor. |
| Cellular location | Golgi apparatus, where glycosyltransferases catalyze sequential sugar addition. |
| Disease relevance | Cancer progression, neuronal function, and host-pathogen interactions. |
What Is GO:0016266?
GO:0016266 is defined as a glycoprotein biosynthetic process starting with the covalent linkage of an N-acetyl-galactosamine via an alpha-glycosidic bond to the oxygen atom of a serine or threonine side chain in a protein, which can be further elongated with the sequential addition of sugar units resulting in the formation of a protein O-linked glycan. In simpler terms, it is the first committed step and subsequent elaboration of mucin-type O-glycans on proteins, beginning with GalNAc attachment to Ser/Thr residues.
Why Is protein O-linked glycosylation via N-acetylgalactosamine Important in Cell Biology?
GO:0016266 is important because O-GalNAc glycosylation is one of the most abundant post-translational modifications on secreted and membrane proteins, and its dysregulation is linked to cancer, neurological disorders, and infectious disease. The process controls the display of tumor-associated carbohydrate antigens such as Tn and sialyl-Tn, which correlate with poor prognosis in multiple cancers. In addition, O-GalNAc glycans on host mucus can serve as inhibitory signals that modulate bacterial invasion, highlighting their role in host-microbe interactions. Understanding this pathway is therefore essential for cancer biology, neurobiology, and infection research.
• O-GalNAc glycosylation is initiated by GALNT enzymes and is essential for mucin-type O-glycan biosynthesis.
• GALNT7 promotes hepatocellular carcinoma progression by activating PI3K/AKT signaling via O-glycosylation of MUC13.
• GALNT4 promotes stemness in non-small cell lung cancer through O-glycosylation of MUC5AC via ITGB4/PI3K/AKT signaling.
• GalNAc-T13 maintains neurite architecture and memory retention via O-GalNAc glycosylation of seizure protein 6.
• Mucus-derived glycans act as inhibitory signals for Salmonella Typhimurium SPI-1-mediated invasion.
• The N-acetylgalactosamine salvage pathway enables metabolic labeling of O-linked glycoproteins for detection and proteomics.
• O-glycan recognition and function are conserved in mice and human cancers, making animal models valuable for study.
• GlycoRNA-L and glycoRNA-S can mediate human monocyte adhesion via binding to Siglec-5, linking glycosylation to immune cell behavior.
• Tunicamycin biosynthesis studies provide insight into natural product glycosylation pathways that can inform glycoengineering.
• O-GalNAc glycosylation is a potential therapeutic target in oncology and immunology.
What Happens During protein O-linked glycosylation via N-acetylgalactosamine?
Initiation by GALNT-mediated GalNAc transfer
In simple terms: The first step is attaching a sugar called GalNAc to a protein.
The process begins in the Golgi apparatus when a member of the GALNT family transfers N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the hydroxyl group of a serine or threonine residue on a target protein, forming an alpha-O-glycosidic bond. This creates the Tn antigen, the minimal O-GalNAc structure. Different GALNT isoforms exhibit distinct tissue expression and substrate preferences, allowing selective modification of proteins such as MUC13 and MUC5AC.
Elongation and processing of O-glycans
In simple terms: After the first sugar is attached, more sugars are added to build a chain.
Following initiation, the O-GalNAc structure can be elongated by sequential addition of galactose, N-acetylglucosamine, fucose, and sialic acid residues, generating core 1-8 O-glycan structures. These elongation steps are catalyzed by distinct glycosyltransferases and produce mature mucin-type O-glycans that can be recognized by lectins and antibodies. The resulting glycans influence protein conformation, stability, and interactions.
Subcellular localization and trafficking
In simple terms: The sugar coating is added in the cell's packaging center.
O-GalNAc glycosylation occurs primarily in the Golgi apparatus, where glycosyltransferases are anchored. The modified proteins then traffic to the cell surface or are secreted. The glycan structures can modulate protein trafficking and cell surface retention, as seen for mucins and receptors.
Recognition by lectins and signaling modulation
In simple terms: The sugar chains are read by other proteins that trigger signals.
O-GalNAc glycans are recognized by lectins such as Siglecs and galectins, which can modulate immune cell adhesion and signaling. For example, glycoRNA-L and glycoRNA-S mediate human monocyte adhesion via binding to Siglec-5. In cancer, O-glycosylation of MUC13 and MUC5AC can activate PI3K/AKT signaling, promoting proliferation and stemness.
Metabolic labeling and detection
In simple terms: Scientists can feed cells a modified sugar to tag glycosylated proteins.
The N-acetylgalactosamine salvage pathway allows metabolic labeling of O-linked beta-N-acetylglucosamine-modified proteins, enabling detection and enrichment of O-GalNAc-modified proteins. This chemical biology approach is valuable for identifying new substrates and studying dynamics of O-glycosylation.
Key Genes Involved in GO:0016266 protein O-linked glycosylation via N-acetylgalactosamine
The following genes encode enzymes and proteins directly involved in or regulated by protein O-linked glycosylation via N-acetylgalactosamine, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GALNT1 | Initiates O-GalNAc glycosylation by transferring GalNAc to Ser/Thr | Foundational enzyme for mucin-type O-glycan biosynthesis |
| GALNT2 | O-GalNAc transferase with tissue-specific substrates | Implicated in lipid metabolism and cancer |
| GALNT3 | O-GalNAc transferase, modifies FGF23 | Regulates phosphate homeostasis; disease models |
| GALNT4 | O-glycosylates MUC5AC | Promotes stemness in non-small cell lung cancer via ITGB4/PI3K/AKT |
| GALNT7 | O-glycosylates MUC13 | Promotes hepatocellular carcinoma progression via PI3K/AKT |
| GALNT13 | O-GalNAc glycosylates seizure protein 6 | Maintains neurite architecture and memory retention |
| MUC13 | Mucin substrate of GALNT7 | O-glycosylation activates PI3K/AKT in liver cancer |
| MUC5AC | Mucin substrate of GALNT4 | O-glycosylation promotes stemness in lung cancer |
| SEZ6 | Seizure protein 6, substrate of GalNAc-T13 | O-GalNAc glycosylation required for neuronal function |
| ITGB4 | Integrin beta 4, signaling partner | Mediates GALNT4-driven PI3K/AKT activation in NSCLC |
| PIK3CA | PI3K catalytic subunit | Downstream effector of O-glycan signaling |
| AKT1 | Serine/threonine kinase | Activated by O-glycan-mediated PI3K signaling |
| SIGLEC5 | Sialic acid-binding lectin | Binds glycoRNA-L/S to mediate monocyte adhesion |
| B3GALT1 | Core 1 synthase | Elongates O-GalNAc glycans |
| C1GALT1 | Core 1 beta3-galactosyltransferase | Essential for O-glycan elongation |
| ST6GALNAC1 | Sialyltransferase | Adds sialic acid to Tn antigen, forming sialyl-Tn |
| GCNT1 | Core 2 beta-1,6-N-acetylglucosaminyltransferase | Branches O-glycans, affects immune cell ligands |
How Is protein O-linked glycosylation via N-acetylgalactosamine Regulated?
O-GalNAc glycosylation is regulated at multiple levels. Expression of GALNT genes is tissue-specific and can be altered in cancer, leading to aberrant O-glycan structures. The availability of UDP-GalNAc, the sugar donor, influences transferase activity, and the N-acetylgalactosamine salvage pathway can modulate substrate supply. In cancer, oncogenic signaling pathways such as PI3K/AKT can be activated by O-glycosylated mucins, creating a feed-forward loop. Additionally, host-derived mucus glycans can act as environmental signals that regulate bacterial invasion programs, indicating that O-glycans participate in host-pathogen regulatory circuits.
protein O-linked glycosylation via N-acetylgalactosamine and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GALNT7 | Hepatocellular carcinoma progression via MUC13 O-glycosylation | Knockout or overexpression in liver cancer cell lines; xenograft models |
| GALNT4 | Non-small cell lung cancer stemness via MUC5AC O-glycosylation | Knockout or overexpression in NSCLC cell lines; spheroid assays |
| GALNT13 | Neurite architecture and memory retention via SEZ6 O-glycosylation | Knockout mice; primary neuron cultures |
| MUC13 | Downstream effector of GALNT7 in liver cancer | Point mutation of glycosylation sites; knock-in models |
| MUC5AC | Downstream effector of GALNT4 in lung cancer | Overexpression and knockout in lung cancer cells |
O-GalNAc glycosylation in cancer
Altered O-GalNAc glycosylation is a hallmark of many cancers. GALNT7 promotes hepatocellular carcinoma progression by activating PI3K/AKT signaling via O-glycosylation of MUC13. Similarly, GALNT4 promotes stemness in non-small cell lung cancer through O-glycosylation of MUC5AC via ITGB4/PI3K/AKT signaling. These findings suggest that targeting GALNT enzymes or their substrates could be a therapeutic strategy. O-glycan recognition and function in mice and human cancers have been extensively reviewed, highlighting the importance of this pathway in tumor biology.
O-GalNAc glycosylation in neuronal function
In the nervous system, GalNAc-T13 maintains neurite architecture and memory retention via O-GalNAc glycosylation of seizure protein 6. This indicates that O-GalNAc glycosylation is critical for neuronal connectivity and cognitive function. Dysregulation of this process may contribute to neurodegenerative or neurodevelopmental disorders, although further studies are needed.
Host-pathogen interactions and immunity
Mucus-derived glycans, which include O-GalNAc structures, act as inhibitory signals for Salmonella Typhimurium SPI-1-mediated invasion. This suggests that host O-glycans can modulate bacterial virulence. Additionally, glycoRNA-L and glycoRNA-S mediate human monocyte adhesion via binding to Siglec-5, linking O-GalNAc-related glycans to immune cell trafficking. These interactions highlight the role of O-glycans in infection and immunity.
From protein O-linked glycosylation via N-acetylgalactosamine-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GALNT7 affect hepatocellular carcinoma growth? | GALNT7 knockout in liver cancer cell lines and mouse xenografts |
| Does GALNT4-mediated O-glycosylation of MUC5AC drive lung cancer stemness? | GALNT4 knockout or overexpression in NSCLC cells; stemness assays |
| Is GalNAc-T13 required for neurite outgrowth and memory? | GalNAc-T13 knockout mice; behavioral and neuronal morphology studies |
| Do specific O-glycosylation sites on MUC13 mediate PI3K/AKT activation? | Point mutations of Ser/Thr to Ala in MUC13; knock-in cell lines |
| Can metabolic labeling identify new O-GalNAc substrates? | Cells treated with GalNAc analogs; click chemistry detection |
| Do mucus glycans inhibit Salmonella invasion? | In vitro invasion assays with mucin-derived glycans |
How to Study the protein O-linked glycosylation via N-acetylgalactosamine Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Glycoproteomics (LC-MS/MS) | Site-specific O-GalNAc modifications | Mapping O-glycosylation sites on proteins |
| Metabolic labeling with GalNAc analogs | Incorporation of tagged sugars into O-glycans | Detection and enrichment of O-GalNAc proteins |
| CRISPR knockout screens | Gene requirements for O-glycosylation | Identifying regulators of cancer cell growth |
| Antibody-based detection (IHC, flow) | Expression of O-glycan epitopes | Tumor tissue profiling |
| Lectin blotting | Presence of specific O-glycan structures | Validation of glycosylation changes |
| In vitro glycosyltransferase assays | Enzyme activity of GALNTs | Kinetic characterization of GALNT isoforms |
| Mouse models (knockout/transgenic) | In vivo function of O-glycosylation | Cancer and neurobiology studies |
Glycoproteomics and mass spectrometry
Mass spectrometry-based glycoproteomics enables site-specific identification of O-GalNAc modifications on proteins. Enrichment of glycopeptides using lectins or chemical labeling followed by LC-MS/MS can reveal the O-glycoproteome and its dynamics.
Metabolic labeling with GalNAc analogs
The N-acetylgalactosamine salvage pathway allows incorporation of azide- or alkyne-tagged GalNAc analogs into O-linked glycoproteins, enabling click chemistry detection and enrichment. This method is useful for tracking O-GalNAc glycosylation in live cells and identifying new substrates.
CRISPR screens and functional genomics
CRISPR knockout screens targeting glycosyltransferases can identify genes required for O-GalNAc glycosylation and its downstream functions. Such screens have been used to uncover regulators of cancer cell growth and immune recognition.
Antibody-based detection and imaging
Antibodies against Tn, sialyl-Tn, and other O-glycan epitopes allow detection of O-GalNAc structures by flow cytometry, immunohistochemistry, and immunofluorescence. These tools are widely used to assess O-glycan expression in tissues and cells.
How CRISPR Can Be Used to Study GO:0016266 protein O-linked glycosylation via N-acetylgalactosamine
Knockout
CRISPR knockout of GALNT genes, such as GALNT7 or GALNT4, can abolish specific O-GalNAc modifications and reveal their roles in cancer cell proliferation, stemness, and signaling. Knockout of GalNAc-T13 in mice impairs neurite architecture and memory retention.
Point Mutation
Point mutations of serine or threonine residues to alanine in substrate proteins like MUC13 or MUC5AC can prevent O-GalNAc attachment at specific sites, allowing dissection of site-specific functions.
Knock-in
Knock-in of tagged or mutant GALNT alleles can be used to study enzyme localization, substrate specificity, and dynamics in vivo. For example, knock-in of fluorescently tagged GalNAc-T13 could reveal its trafficking in neurons.
Overexpression
Overexpression of GALNT7 or GALNT4 in cancer cell lines enhances O-glycosylation of MUC13 or MUC5AC, activating PI3K/AKT signaling and promoting malignant phenotypes. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports protein O-linked glycosylation via N-acetylgalactosamine Research
Researchers studying protein O-linked glycosylation via N-acetylgalactosamine-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. EDITGENE provides custom CRISPR cell models and screening services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for protein O-linked glycosylation via N-acetylgalactosamine research.
Frequently Asked Questions About protein O-linked glycosylation via N-acetylgalactosamine
What is protein O-linked glycosylation via N-acetylgalactosamine?
It is the biological process (GO:0016266) that begins with the attachment of N-acetylgalactosamine (GalNAc) to serine or threonine residues on proteins, forming mucin-type O-glycans that can be further elongated.
What genes are involved in protein O-linked glycosylation via N-acetylgalactosamine?
Key genes include the GALNT family (e.g., GALNT1, GALNT2, GALNT3, GALNT4, GALNT7, GALNT13), as well as downstream glycosyltransferases like C1GALT1, B3GALT1, ST6GALNAC1, and GCNT1.
What is the function of O-GalNAc glycosylation?
It modifies proteins to influence their stability, trafficking, and interactions, and it plays roles in cell signaling, immune recognition, and cancer progression.
Which enzymes initiate O-GalNAc glycosylation?
UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases (GALNTs) initiate the process by transferring GalNAc to Ser/Thr.
How is O-GalNAc glycosylation linked to cancer?
GALNT7 promotes hepatocellular carcinoma via MUC13 O-glycosylation and PI3K/AKT activation, while GALNT4 promotes lung cancer stemness via MUC5AC O-glycosylation.
What is the role of GalNAc-T13 in the nervous system?
GalNAc-T13 maintains neurite architecture and memory retention through O-GalNAc glycosylation of seizure protein 6.
Can O-GalNAc glycosylation be studied with metabolic labeling?
Yes, the N-acetylgalactosamine salvage pathway allows incorporation of labeled GalNAc analogs into O-linked glycoproteins for detection and enrichment.
How do mucus glycans affect bacterial invasion?
Mucus-derived glycans act as inhibitory signals for Salmonella Typhimurium SPI-1-mediated invasion.
What are the synonyms for GO:0016266?
Synonyms include core O-glycan biosynthetic process, mucin-type O-glycan synthesis, O-glycan processing, protein O-linked GalNAcylation, and protein O-linked glycosylation via N-acetylgalactosamine.
How can CRISPR be used to study O-GalNAc glycosylation?
CRISPR knockout, point mutation, knock-in, and overexpression models can be used to dissect the roles of GALNT genes and glycosylation sites in cellular processes and disease.
Conclusion
Protein O-linked glycosylation via N-acetylgalactosamine (GO:0016266) is a fundamental post-translational modification that shapes the glycocalyx and influences diverse biological processes, from cancer progression to neuronal function and host-pathogen interactions. The GALNT enzyme family and downstream glycosyltransferases orchestrate this pathway, and their dysregulation is linked to human diseases. Continued research using CRISPR models, glycoproteomics, and metabolic labeling will further illuminate the mechanisms and therapeutic potential of O-GalNAc glycosylation.
References
- 1. Li Y et al.. 2025. GlycoRNA-L and glycoRNA-S mediate human monocyte adhesion via binding to Siglec-5.. Biochim Biophys Acta Mol Cell Res 1872(7):120017 PMID: 40609958
- 2. Deng Y et al.. 2026. GalNAc-T13 maintains neurite architecture and memory retention via O-GalNAc glycosylation of seizure protein 6.. Proc Natl Acad Sci U S A 123(10):e2508476123 PMID: 41790942
- 3. Wheeler KM et al.. 2025. Mucus-derived glycans are inhibitory signals for Salmonella Typhimurium SPI-1-mediated invasion.. Cell Rep 44(10):116304 PMID: 40992372
- 4. Boyce M et al.. 2011. Metabolic cross-talk allows labeling of O-linked beta-N-acetylglucosamine-modified proteins via the N-acetylgalactosamine salvage pathway.. Proc Natl Acad Sci U S A 108(8):3141-6 PMID: 21300897
- 5. Cervoni GE et al.. 2020. O-glycan recognition and function in mice and human cancers.. Biochem J 477(8):1541-1564 PMID: 32348475
- 6. Price NP et al.. 2007. Biosynthesis of the tunicamycins: a review.. J Antibiot (Tokyo) 60(8):485-91 PMID: 17827659
- 7. Liang L et al.. 2025. GALNT7 promotes hepatocellular carcinoma progression by activating the PI3K/AKT signaling pathway via O-glycosylation of MUC13.. Acta Biochim Biophys Sin (Shanghai) 58(2):322-336 PMID: 41439366
- 8. Guo Y et al.. 2025. GALNT4 promotes the stemness of non-small cell lung cancer through O-glycosylation of MUC5AC via ITGB4/PI3K/AKT signaling pathway.. Cell Signal 134:111934 PMID: 40505844
